Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Biocept Inc (BIOC)

Biocept Inc (BIOC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Biocept Reports 2022 Financial Results

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the 12 months ended December 31, 2022 and provides a business update....

BIOC : 0.4349 (-13.05%)
Enrollment Begins in FORESEE Clinical Trial Using Biocept’s CNSide™ to Evaluate Patients with Leptomeningeal Metastases

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces enrollment of the first patient in the FORESEE clinical trial with the Company’s proprietary...

BIOC : 0.4349 (-13.05%)
Biocept Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, today announced that it has granted inducement stock options to purchase an aggregate of 7,360 shares...

BIOC : 0.4349 (-13.05%)
Biocept to Explore Strategic Alternatives and Implement Restructuring Plan

Biocept, Inc. (NasdaqCM: BIOC ) today announced that it has commenced a process to explore and evaluate strategic alternatives to enhance shareholder value. Biocept has engaged EF Hutton, division of...

BIOC : 0.4349 (-13.05%)
Biocept Reports Third Quarter 2022 Financial Results

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and nine months ended September 30, 2022 and provides a...

BIOC : 0.4349 (-13.05%)
Biocept Appoints Financial Executive Quyen Dao-Haddock to its Board of Directors

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces the appointment of Quyen Dao-Haddock to its Board of Directors, effective immediately,...

BIOC : 0.4349 (-13.05%)
Biocept Announces Participation in an Investigator-Initiated Study to Better Understand the Development and Progression of Metastatic Breast Cancer to the Central Nervous System

Biocept, Inc . (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces a collaboration agreement to participate in an investigator-initiated, non-therapeutic...

BIOC : 0.4349 (-13.05%)
Assure Holdings Corp. (IONM) Reports Q3 Loss, Lags Revenue Estimates

Assure Holdings Corp. (IONM) delivered earnings and revenue surprises of -28.57% and 17.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

IONM : 0.4300 (-9.66%)
BIOC : 0.4349 (-13.05%)
Agiliti (AGTI) Q3 Earnings Surpass Estimates

Agiliti (AGTI) delivered earnings and revenue surprises of 5.56% and 1.27%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AGTI : 10.05 (-0.50%)
BIOC : 0.4349 (-13.05%)
Biocept Reports Second Quarter 2022 Financial Results

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three and six months ended June 30, 2022 and provides a business...

BIOC : 0.4349 (-13.05%)

Barchart Exclusives

3 Cheapest Dividend Kings To Buy Today
This article covers three buy-rated companies that've increased their dividends for 50+ consecutive years. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar